Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing

Table 7

Multinomial logistic regression analysis to evaluate the association between the presence of BRAF^V600E and patient characteristics of PTMC.

Independent variable	OR	CI 95%
Gender
F	1	—	Ref.
M	1.49	0.66–3.37	0.324
Age at diagnosis (years)
≤40	0.46	0.07–3.00	0.455
(40, 60]	0.24	0.04–1.46	0.089
>60	1	—	Ref.
Maximum tumor size (mm)
≤5	1	—	Ref.
>5	4.92	2.40-10.07	<0.001
Chronic lymphocytic thyroiditis
No	1	—	Ref.
Yes	0.7	0.31–1.60	0.401
Bilateralism
No	1	—	Ref.
Yes	0.6	0.19–1.90	0.686
Multifocality
No	1	—	Ref.
Yes	5.12	1.48-17.70	0.996
Intrathyroid spread
No	1	—	Ref.
Yes	1.02	0.10-10.25	0.67
Extrathyroidal extension
No	1	—	Ref.
Yes	2.39	0.73–7.78	0.749
Lymph node metastases
No	1	—	Ref.
Central compartment	2.53	0.78–8.21	0.481
Laterocervical compartment	8	0.65–98.99	0.627
Central +	2.9	0.54-15.57	0.985
Laterocervical compartment
≤5	1	—	Ref.
>5	0.85	0.23–3.09	0.625
Staging (VIII ed. TNM)
I	1	—	Ref.
II	3.68	0.54-25.15	0.256
Tumor recurrence
Yes	0.66	0.51–8.60	0.877
No	1	—	Ref.
n.a.	0.03	0.00–0.59	0.048

na: not available and PTMC: papillary thyroid microcarcinoma. Significant differences are shown in bold characters .